Last reviewed · How we verify

NCT06115317: HHIC

Homonymous Hemianopia in Childhood

Status unknown NA Last updated 3 November 2023
What this trial tests

NA trial testing Prism in Homonymous Hemianopia in 25 participants. Status unknown.

Timeline
4 May 2023
Primary endpoint
31 March 2024
1 July 2025

Quick facts

Lead sponsorInstitute of Child Health
PhaseNA
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationrandomized
Designcrossover
Maskingtriple
Primary purposeother
Enrollment25
Start date4 May 2023
Primary completion31 March 2024
Estimated completion1 July 2025
Sites1 location across United Kingdom

Drugs / interventions tested

Conditions studied

Sponsor

Institute of Child Health

Who can join

Adults 5 to 17, any sex, with Homonymous Hemianopia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The study will consist of two connected components at a single centre. Phase 1 is observational, phenotyping children with Homonymous hemianopia (HH). Phase 2 is a pilot double blind cross over RCT in which segmental prisms are compared with sham prisms in glasses.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Prism

Trials testing the same drug.

Other recruiting trials for Homonymous Hemianopia

Currently open trials in the same condition.

Other Institute of Child Health trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06115317.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing